Evidence map›Paper›PMID 33107700›Full record

ArticleThoracic cancer2020

Serum exosomal miR-1269a serves as a diagnostic marker and plays an oncogenic role in non-small cell lung cancer.

Xue Wang, Xinquan Jiang, Juan Li, Jingzheng Wang, Helen Binang, Shuang Shi, Weili Duan, Yinghui Zhao, Yi Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Xue Wang *School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, China.
Xinquan Jiang *School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, China.
Juan LiDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
Jingzheng WangDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
Helen BinangDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
Shuang ShiDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
Weili DuanDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
Yinghui ZhaoDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
Yi ZhangRespiratory and Critical Care Medicine Department, Qilu Hospital, Shandong University, Jinan, China.ORCID 0000-0003-2843-7645
Second Hospital of Shandong University · CNZero to Three · USQilu Hospital of Shandong University · CNTaiping Hospital · MY

Funding

National Natural Science Foundation of China 81400029
6 · The paper itself

Abstract

backgroundEarly diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here, we explored a panel of miRNAs for NSCLC diagnosis and functionally characterized miR-1269a in the pathogenesis of NSCLC.

methodsFirst, we analyzed high-throughput data from The Cancer Genome Atlas (TCGA) to identify differentially expressed miRNAs between NSCLC patients and healthy controls. We examined the expression profiles of the identified miRNAs using qRT-PCR.

resultsWe found that four micro-RNAs (hsa-miR-9-3p, hsa-miR-205-5p, hsa-miR-210-5p, and hsa-miR-1269a) were more abundant in serum exosomes from NSCLC patients. A logistic regression model validated the diagnostic efficacy of the four-microRNA panel, allowing us to distinguish NSCLC patients from healthy controls with AUCs of 0.915 and 0.878 for the training and validation sets, respectively. Functionally, NSCLC cell proliferation, migration, and invasion were affected by the aberrant expression of hsa-miR-1269a in culture. Reduced expression of miR-1269a resulted in reduced proliferation, migration, and invasion through targeting the forkhead box O1 gene (FOXO1).

conclusionsTaken together, our study identified a panel of four serum exosomal miRNAs as a potential noninvasive diagnostic biomarker for NSCLC. The interactions between FOXO1 and miR-1269a represent novel potential targets for NSCLC therapy.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungExosomesFemaleForkhead Box Protein O1HumansLung NeoplasmsMaleMicroRNAsPrognosisTransfectionBiomarkers, TumorForkhead Box Protein O1FOXO1 protein, humanMicroRNAsMIR205, humanMIRN1269 microRNA, humanMIRN210 microRNA, humanMIRN92 microRNA, humanDiagnostic markerFOXO1mir-1269aNSCLCserum exosomes

Identifiers

PMID33107700
PMCPMC7705625
OpenAlexW3094516255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.